Also trades as: 0VQA.L (LSE) · $vol 0M
VKTX NASDAQ
Viking Therapeutics, Inc.
1W: -6.8%
1M: -24.6%
3M: -25.5%
YTD: -29.7%
1Y: -27.7%
3Y: +148.3%
5Y: +326.4%
$24.89
+0.68 (+2.81%)
Weekly Expected Move ±9.4%
$20
$22
$24
$27
$29
Credit Risk of going bust: lower than 84% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Viking Therapeutics, Inc. would be worth roughly what it owes.
Total debt $4.1M against a stock market value of $3.17B.
Distance to default 10.83 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.0M (short-term plus half of long-term), stock volatility 66.3%; Altman Z'' -5.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Viking Therapeutics, Inc. would be worth roughly what it owes.
Total debt $4.1M against a stock market value of $3.17B.
Distance to default 10.83 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.0M (short-term plus half of long-term), stock volatility 66.3%; Altman Z'' -5.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2025-03-11
Earliest Filing
2025-03-11
Latest Filing
supplier: 5
Counterparties (Filed by VKTX)
5 relationshipsCompanies named in VKTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Corden Pharma Schweizerhalle GmbH | — | supplier | Manufactures and supplies VK2735 API and fill/finish services under strategic agreements. | 2025-03-11 | View |
| Corden Pharma GmbH | — | supplier | Manufactures and supplies VK2735 API and fill/finish services under strategic agreements. | 2025-03-11 | View |
| Corden Pharma Colorado, Inc. | — | supplier | Manufactures and supplies VK2735 API under strategic agreements. | 2025-03-11 | View |
| Corden Pharma Lisbon S.A. | — | supplier | Manufactures and supplies VK2735 fill/finish services under strategic agreements. | 2025-03-11 | View |
| Corden Pharma S.p.A. | — | supplier | Manufactures and supplies VK2735 fill/finish services under strategic agreements. | 2025-03-11 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-28 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-09-22 | Other Events; Exhibits | View | |
| 2026-07-29 | Earnings Release; Exhibits | View | |
| 2026-05-26 | Shareholder Vote; Exhibits | View | |
| 2026-04-29 | Earnings Release; Exhibits | View | |
| 2026-02-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-22 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-19 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-07-23 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-27 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-04-23 | Changes in Registrant's Certifying Accountant; Other Events; Financial Statements and Exhibits | View | |
| 2025-04-23 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-11 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Other Events; Fin | Agreement | View |
| 2025-02-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-04 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-10-23 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-07-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-04 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-05-23 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2024-04-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR